ACEIs or ARBs, BBs, and MRAs have been documented to improve clinical status and survival of patients with CHF.2 The proven effects of ACE inhibition to prolong survival support their use as first-line agents in the management of CHF.6 Only 58.8% of our patients were prescribed ACEIs or ARBs owing to a lower range of blood pressure or fear of worsening renal function. The gene discussed is ACE; the disease is congestive heart failure.